Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures~* Adult male and non-pregnant, non-lactating females~* Documented evidence of chronic hepatitis B virus (HBV) infection previously~* Maintained on tenofovir disoproxil fumarate (TDF) 300 mg once daily for at least 48 weeks, and as monotherapy for chronic hepatitis B for at least 24 weeks with viral suppression (HBV DNA \< lower limit of quantitation) for a minimum of 12 weeks prior to screening~* Adequate renal function~* Normal Electrocardiogram~Key Exclusion Criteria:~* Pregnant women or women who are breastfeeding~* Males and females of reproductive potential who are unwilling to use an effective, protocol-specified method(s) of contraception during the study.~* Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus (HIV)~* Evidence of hepatocellular carcinoma~* Current evidence of, or recent (≤ 5 year) history of clinical hepatic decompensation~* Abnormal hematological and biochemical parameters, including:~  * Hemoglobin \< 10 g/dL~ * Absolute neutrophil count \< 750/mm\^3~ * Platelets ≤ 50,000/mm\^3~ * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 5 × upper limit of the normal (ULN)~ * Albumin \< 3.0 mg/ dL~ * International normalized ratio (INR) \> 1.5 × ULN (unless stable on anticoagulant regimen)~ * Total bilirubin \> 2.5 × ULN~* Received solid organ or bone marrow transplant~* Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (eg, basal cell skin cancer). Individuals under evaluation for possible malignancy are not eligible.~* Currently receiving therapy with immunomodulators (eg, corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion~* Individuals receiving ongoing therapy with drugs not to be used with TAF or TDF or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients~* Current alcohol or substance abuse judged by the investigator to potentially interfere with compliance~* Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements.~* Use of investigational agents within 3 months of screening, unless allowed by the sponsor~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAF 25 mg (Type: EXPERIMENTAL): Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
- TDF 300 mg (Type: ACTIVE_COMPARATOR): DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).